Gallbladder Cancer Market Report and Forecast 2024-2032

Gallbladder Cancer Market Outlook

The gallbladder cancer market size was valued at USD 87.57 million in 2023, driven by the increasing research and development activities for new treatment among people across the 7 major markets. The market size is anticipated to grow at a CAGR of 5.56% during the forecast period of 2024-2032 to achieve a value of USD 142.5 million by 2032.

Gallbladder Cancer: Introduction

Gallbladder cancer originates from abnormal cell growth within the gallbladder, a small, pear-shaped organ located beneath the liver on the right side of the abdomen. Responsible for storing bile, a digestive fluid produced by the liver, the gallbladder plays a crucial role in the digestive process. Though uncommon, gallbladder cancer poses a significant challenge due to its tendency to remain asymptomatic in its early stages, often leading to late detection and a poor prognosis. The insidious nature of this cancer is exacerbated by its subtle symptoms or the absence thereof, allowing it to progress unnoticed.

Common signs such as upper right abdominal pain, bloating, unexplained weight loss, and jaundice, characterized by yellowing of the skin and eyes, might indicate the presence of gallbladder cancer, but these indicators often manifest in later stages, complicating timely diagnosis and treatment.

Gallbladder Cancer Market Analysis

The market for gallbladder cancer treatment is witnessing a transformative phase, driven by several key factors. The rise in demand and emphasis on targeted therapy treatments is further anticipated to bolster the gallbladder cancer market growth. For example, Gemcitabine, a combination therapy, has shown promising results, indicating an increased response rate compared to traditional treatments using 5-FU alone. The efficacy of gemcitabine in conjunction with cis-platinum and capecitabine highlights its potential as a viable treatment option.

Pembrolizumab has also shown positive results in tumours with high microsatellite instability/deficient mismatch repair, and entrectinib, a tyrosine kinase inhibitor, has potential use in NTRK gene fusion-positive tumours, providing a new pathway for gallbladder cancer treatment. These developments signify a shift towards more targeted and potentially more effective therapies, exhibiting hopeful market growth.

Gallbladder Cancer Market Segmentations

Market Breakup by Type

• Stage I

• Stage II

• Stage III

• Stage IV

Market Breakup by Diagnosis Type

• Physical Examination

• Liver Function Test

• Blood Test

• CT Scan

• Ultrasound

• Percutaneous Transhepatic Cholangiography (PTC)

• Endoscopic Retrograde Cholangiopancreatography (ERC)

• Magnetic Resonance Imaging (MRI)

• Endoscopic ultrasound (EUS)

• Laparoscopy

• Biopsy

Market Breakup by Treatment

• Surgery

• Radiation Therapy

• Chemotherapy

• Immunotherapy

Market Breakup by Route of Administration

• Oral

• Injections

Market Breakup by End User

• Hospitals

• Gynaecology Clinics

• Academic and Research Centers

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Gallbladder Cancer Market Overview

The market is experiencing significant growth driven by the rising prevalence of gallbladder cancer, especially among the geriatric population, which underscores the urgency for precision treatments. The statistics projected by the American Cancer Society for 2023 in the United States display concern by mentioning that a substantial number of new cases and related deaths are anticipated to occur in 2023. This surge in cases, particularly gallbladder cancers, signifies an unmet need for more effective therapies and diagnostic tools, further bolstering the gallbladder cancer market demand. The market is poised for further growth, primarily fueled by advancements in diagnostic technologies and the emergence of innovative therapeutics in the market.

The United States has been dominating the markets and is expected to lead the market in forecast period. This growth can be attributed to the increasing incidence of gallbladder cancer, the presence of key industry players, and the robust healthcare infrastructure in the region. Rising research and development continue to pave the way for novel interventions and diagnostic methods, contributing significantly to the rising gallbladder cancer market share, addressing critical healthcare gaps, and offering hope to affected individuals.

Gallbladder Cancer Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Cipla Inc.

• Bristol-Myers Squibb Company

• Eli Lilly and Company

• Pfizer Inc.

• F. Hoffmann-La Roche Ltd

• Sanofi

• OncoTherapy Science, Inc.

• Intuitive Surgical

• Sun Pharmaceutical Industries

• GLS Pharma Ltd.

• Symmetry Surgical Inc.

• CONMED Corporation

• Olympus Corporation

• Boston Scientific Corporation

Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report